Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript

Operator

Greetings, and welcome to the Corbus Pharmaceuticals 2026 ASCO Data Update Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. [Operator Instructions]

It’s now my pleasure to turn the call over to Dan Ferry, Managing Director with LifeSci Advisors.

Daniel Ferry
Lifesci Advisors, LLC

Thank you, operator. Good morning, everyone, and welcome to the Corbus Pharmaceuticals 2026 ASCO Data update call.

As a reminder, during this call, we will be making forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly reports on Form 10-K — reports on Form 10-Q and annual report on Form 10-K and cautionary statements made during this call. We assume no obligation to update any of these forward-looking statements or information.

It is now my pleasure to turn the call over to your host, Dr. Yuval Cohen, CEO of Corbus.

Yuval Cohen
CEO & Director

Thank you, Dan, and good morning, everyone, for joining us. It’s my pleasure to provide a detailed overview of the data we will be presenting at ASCO in just a few days’ time. This data represents an April 1 data cut.